Lozano Sánchez, F.S.; Carnicero Martínez, J.A.; Méndez-García, L.; García-Cenador, M.B.; Pericacho, M. Endoglin and Other Angiogenesis Markers in Recurrent Varicose Veins. J. Pers. Med.2022, 12, 528.
Lozano Sánchez, F.S.; Carnicero Martínez, J.A.; Méndez-García, L.; García-Cenador, M.B.; Pericacho, M. Endoglin and Other Angiogenesis Markers in Recurrent Varicose Veins. J. Pers. Med. 2022, 12, 528.
Lozano Sánchez, F.S.; Carnicero Martínez, J.A.; Méndez-García, L.; García-Cenador, M.B.; Pericacho, M. Endoglin and Other Angiogenesis Markers in Recurrent Varicose Veins. J. Pers. Med.2022, 12, 528.
Lozano Sánchez, F.S.; Carnicero Martínez, J.A.; Méndez-García, L.; García-Cenador, M.B.; Pericacho, M. Endoglin and Other Angiogenesis Markers in Recurrent Varicose Veins. J. Pers. Med. 2022, 12, 528.
Abstract
Abstract: Background: Surgery on varicose veins (crossectomy and stripping) leads to recurrence and has clinical and socio-economic repercussions. Their etiopathogenesis has yet to fully under-stood. Objective: Study the expression of endoglin and other molecules involved in the neovascu-larisation process in patients suffering from this disease. Methods: 43 patients that have undergone surgery for varicose veins (24 primary and 19 recurrent). They were identified on the venous wall (proximal -saphenofemoral junction- and distal), via real-time RT-PCR, and in serum, via ELISA: Endoglin (Eng), Vascular Endothelial Growth Factor (VEGF-A), its receptors 1 and 2 (VEGFR1 or FLT1), (VEGFR2 or FLK), and the Hypoxia-Inducible Factor (HIF-1A). All the patients signed a con-sent form. Results: The recurrent group recorded a higher expression of Eng, VEGF-A, VEGFR1 and VEGFR2 at the level of proximal venous wall compared to the primary group. HIF-1A did not record any differences. As regards the determination of the distal venous wall, no markers recorded differ-ences between the groups. Among the serum determinations, only sFLT1 recorded a significant drop among the patients with recurrent varicose veins. Conclusions: Patients with recurrent vari-cose veins record a higher expression of endoglin and other markers of angiogenesis in proximal veins. Endoglin in the blood (sEng) has not proven to be of any use in recurrent varicose veins.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
